Athol Wells

25PUBLICATIONS
111CO-AUTHORS
Immunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRheumatology and arthritis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jan 08, 2026
Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis.

John A Mackintosh, Simon L F Walsh, Mario Silva

|Jan 03, 2025
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis.

Nina R Goldman, Svetlana I Nihtyanova, Claire F Beesley

|Feb 14, 2024
Low bleeding rates following transbronchial lung cryobiopsy in unclassifiable interstitial lung disease.

John Taverner, Carmen M Lucena, Justin L Garner

|Oct 02, 2023
Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases.

Carmel J W Stock, William G Bray, Vasilis Kouranos

|Jan 15, 2023
Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.

Yoshikazu Inoue, Athol U Wells, Jin Woo Song

|Sep 29, 2022
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.

David Roofeh, Kevin K Brown, Ella A Kazerooni

Pageof 5